Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mirum Pharmaceuticals, Inc.

https://mirumpharma.com

Latest From Mirum Pharmaceuticals, Inc.

Orphan Drugs Dominate EU Fast-Track Request Decisions In July

The European Medicines Agency decided this month whether to grant fast-track review for planned marketing authorization applications for four potential new orphan treatments.

Europe Review Pathway

Asia Deal Watch: GC Pharma Looks To Build On Enzyme Replacement Therapy Success

South Korean firm teams with Speragen to develop enzyme-replacement therapy for the genetic disorder and with Mirum for maralixibat. Plus deals involving Takeda/PeptiDream, Hanmi/LegoChem, Sun/Cassiopea, LegoChem/Cellectar, ChubLab/CJ CheilJedang Corp., Alebund/Chugai, Kintor/Fosun, Astellas/ExCellThera and I-Mab/neoX/Immorna.

Deal Watch Asia Pacific

Albireo Dashes Into PFIC Market As FDA, EMA Approve Bylvay

The company anticipates an addressable global market for progressive familial intrahepatic cholestasis of 2,500 patients, with initial plans to focus on around 100 physicians at 60 centers.

Rare Diseases Approvals

Obesity Drug Imcivree Among Eight New Products To Win EMA Nod

The European Medicines Agency today revealed the names of the latest new products it believes should be approved for use across the EU.

Europe Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register